

# Robert A Ritzel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/199447/publications.pdf>

Version: 2024-02-01

14  
papers

4,545  
citations

759233

12  
h-index

1058476

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

5079  
citing authors

#	ARTICLE	IF	CITATIONS
1	Î <sup>2</sup> -Cell Deficit and Increased Î <sup>2</sup> -Cell Apoptosis in Humans With Type 2 Diabetes. <i>Diabetes</i> , 2003, 52, 102-110.	0.6	3,615
2	Relationship Between Î-Cell Mass and Fasting Blood Glucose Concentration in Humans. <i>Diabetes Care</i> , 2006, 29, 717-718.	8.6	184
3	Human Islet Amyloid Polypeptide Oligomers Disrupt Cell Coupling, Induce Apoptosis, and Impair Insulin Secretion in Isolated Human Islets. <i>Diabetes</i> , 2007, 56, 65-71.	0.6	170
4	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018, 41, 2147-2154.	8.6	159
5	Replication Increases Î-Cell Vulnerability to Human Islet Amyloid Polypeptide-Induced Apoptosis. <i>Diabetes</i> , 2003, 52, 1701-1708.	0.6	107
6	Induction of Î <sup>2</sup> -Cell Rest by a Kir6.2/SUR1-Selective KATP-Channel Opener Preserves Î <sup>2</sup> -Cell Insulin Stores and Insulin Secretion in Human Islets Cultured at High (11 mM) Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 795-805.	3.6	72
7	Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 541-548.	4.4	69
8	Glucose Stimulates Pulsatile Insulin Secretion from Human Pancreatic Islets by Increasing Secretory Burst Mass: Dose-Response Relationships. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 742-747.	3.6	53
9	A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. <i>Diabetes Care</i> , 2018, 41, 1672-1680.	8.6	44
10	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2860-2868.	4.4	20
11	Annexin A5 Directly Interacts with Amyloidogenic Proteins and Reduces Their Toxicity. <i>Biochemistry</i> , 2009, 48, 10568-10576.	2.5	19
12	Therapeutic approaches based on beta-cell mass preservation and/or regeneration. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 1835.	3.0	17
13	Beta-cell selective KATP-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. <i>Regulatory Peptides</i> , 2010, 165, 158-162.	1.9	10
14	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 346-354.	4.4	6